Introduction {#s1}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women in the United States ([@B1]--[@B3]). According to American Cancer Society, the expected number of new cases and deaths of CRC in the United States in 2018 is 140,250 and 50,630, respectively ([@B1]). Obesity has already been established as a risk factor of CRC development ([@B4]--[@B8]). The association between body mass index (BMI) and outcomes in patients diagnosed with CRC has been previously described. Analyses of other surrogates of obesity e.g., waist circumference and/or waist-to-hip ratio have shown similar relationship to CRC ([@B9]). The relationship, however, is complex and results remain debatable ([@B10]). There are several patient- and tumor-related factors that affect this and associations are not entirely clear. While some studies especially in early stage colorectal cancers show that obesity as a negative prognostic indicator, in advanced stage patients, being overweight or obese may be protective. The mechanisms in which obesity can impact outcomes in patients with CRC are stage dependent and several factors can lead to the differential outcomes reported. For example, in early stage CRC, a meta-analysis recently published showed increased risk of surgical site infections ([@B11]). While in advanced stage CRC patients, the weight loss and cachexia as part of the disease process may impact patients who are malnourished and/or normal BMI more than overweight or obese patients. Thereby, being overweight or obese may potentially be protective. Furthermore, few studies considered pre- or post-diagnosis weight or BMI change as a variable to estimate the prognosis of CRC ([@B12], [@B13]). Given BMI is a dynamic variable, the impact of drop in BMI or weight, on survival of CRC patients, needs to be further elucidated in order to potentially improve management of these patients.

In this study, our aim was to examine the association between BMI and outcomes in patients who are diagnosed with CRC at our institution, and to estimate their survival patterns. We also tried to study if change in BMI, specifically fall in BMI, was a negative predictor of outcome.

Materials and Methods {#s2}
=====================

Study Design and Data Source
----------------------------

Institutional review board approval was obtained. The Mayo Clinic, 3-site single institution (Arizona, Florida, and Minnesota), cancer registry was queried for all patients seen with a diagnosis of CRC between 1972 and 2017. Twenty-six thousand nine hundred eight patients were identified. The Mayo Clinic Colon and Rectal Cancer Registry is an institutional dataset comprising of patients seen at all of the 3 Mayo Clinic Sites. Patients are identified through the ICD coding, which is subsequently verified based on clinical notes and pathology. This forms the basis of reporting data to other datasets as well. Since this represents data from 3 major academic sites in the country of Mayo Clinic, patients tend to represent population based registries and dataset from other tertiary care institutions in United States. For this particular study, 3,814 patients were found to have either BMI, or height and weight data available to calculate BMI within 6 months prior to cancer diagnosis. To allow for comparisons across patients to be similar and minimize confounding and other disease/treatment variables, we restricted the BMI data to what was available within 6 months of the diagnosis. After excluding patients with BMI \< 10 or \>80 (likely due to inaccurate data entry), a total of 3,799 patients were included in this analysis.

Statistical Analysis
--------------------

Summary statistics for continuous variables are reported as mean (standard deviation) and median (range) while categorical variables are reported as frequency (percentage). The international classification guideline for adult BMI was used to create the following BMI groups: normal (18.50--24.99 kg/m^2^), underweight (\<18.50 kg/m^2^), overweight (25.00--29.99 kg/m^2^), and obese (≥30.00 kg/m^2^). Continuous variables were compared between BMI groups using Kruskal-Wallis test and categorical variables were compared using Chi-squared test. Overall survival rates after diagnosis at 5, 10, and 15- years were estimated using Kaplan-Meier method and compared between groups using log-rank test. Multivariable Cox regression models were used to assess the differences in overall survival between BMI groups in each cancer stage, controlling for age, gender, year of diagnosis, and cancer location. Since proportional hazard assumption was violated for BMI category in stage 2 patients, it was included in the model for stage 2 patients with time dependent coefficients. When analyzing post-diagnosis BMI in stage 4 patients, BMI data was sorted in a way to accommodate the counting process model for time-dependent covariates. BMI was assumed to stay the same between two dates of measurements, as well as from the last BMI measurement to last survival follow up date. The impact of change of BMI at 30, 60, and 90 day on survival afterwards were also analyzed. Again, these cutoffs were chosen arbitrarily to minimize confounding and allow similar comparisons to be made across patients post-diagnosis. The reasons for choosing the BMI change 30, 60, and 90 day was mainly because of expert opinion on what would be clinical meaningful in patients with stage-4 cancer. SAS 9.4 was used for statistical analysis.

Results {#s3}
=======

Patient Demographics and Classification into BMI Categories
-----------------------------------------------------------

Among 3,799 CRC patients included in this study, there were 29% normal weight, 2% underweight, 36% overweight, and 33% obese patients based on the international classification of BMI. The average age at diagnosis was 68.0 (±13.6) and 54% patients were male. The majority of patients (78.3%) were diagnosed with CRC in year 2000 or later (Q1--Q3: 2000--2010). Demographic and baseline variables are demonstrated in Table [1](#T1){ref-type="table"}.

###### 

Demographic and baseline variables.

                                      **Normal weight individuals (*N* = 1,085)**   **Underweight individuals (*N* = 72)**   **Overweight individuals (*N* = 1,369)**   **Obese individuals (*N* = 1,273)**   **Total (*N* = 3,799)**
  ----------------------------------- --------------------------------------------- ---------------------------------------- ------------------------------------------ ------------------------------------- -------------------------
  **Age at diagnosis**                                                              \<0.0001                                                                                                                  
     *N*                              1,085                                         72                                       1,369                                      1,273                                 3,799
     Mean (*SD*)                      68.0 (15.2)                                   65.8 (18.9)                              69.0 (12.9)                                66.6 (12.3)                           67.8 (13.6)
     Median                           71.0                                          69.0                                     71.0                                       68.0                                  70.0
     Q1, Q3                           59.0, 79.0                                    55.5, 80.0                               61.0, 78.0                                 58.0, 75.0                            60.0, 78.0
     Range                            (14.0--97.0)                                  (3.0--93.0)                              (19.0--95.0)                               (17.0--92.0)                          (3.0--97.0)
  **Age at diagnosis**                                                              \<0.0001                                                                                                                  
      \< 50                           156 (14.4%)                                   13 (18.1%)                               130 (9.5%)                                 142 (11.2%)                           441 (11.6%)
     51--60                           146 (13.5%)                                   10 (13.9%)                               193 (14.1%)                                230 (18.1%)                           579 (15.2%)
     61--70                           234 (21.6%)                                   14 (19.4%)                               356 (26.0%)                                361 (28.4%)                           965 (25.4%)
     71--80                           308 (28.4%)                                   17 (23.6%)                               438 (32.0%)                                392 (30.8%)                           1155 (30.4%)
     \>80                             241 (22.2%)                                   18 (25.0%)                               252 (18.4%)                                148 (11.6%)                           659 (17.3%)
  **Year of diagnosis**                                                             0.0001                                                                                                                    
     *N*                              1,085                                         72                                       1,369                                      1,273                                 3,799
     Mean (*SD*)                      2005.1 (6.3)                                  2006.6 (6.0)                             2004.8 (6.4)                               2005.8 (6.1)                          2005.2 (6.3)
     Median                           2005.0                                        2006.5                                   2005.0                                     2006.0                                2005.0
     Q1, Q3                           2000.0, 2010.0                                2001.5, 2013.0                           2000.0, 2010.0                             2001.0, 2011.0                        2000.0, 2010.0
     Range                            (1975.0--2016.0)                              (1995.0--2016.0)                         (1972.0--2016.0)                           (1973.0--2016.0)                      (1972.0--2016.0)
  **Year of diagnosis**                                                             0.0384                                                                                                                    
      \< 1980                         3 (0.3%)                                      0 (0.0%)                                 4 (0.3%)                                   3 (0.2%)                              10 (0.3%)
     1980--2000                       228 (21.0%)                                   10 (13.9%)                               333 (24.3%)                                245 (19.2%)                           816 (21.5%)
     ≥2000                            854 (78.7%)                                   62 (86.1%)                               1032 (75.4%)                               1025 (80.5%)                          2973 (78.3%)
  **Gender**                                                                        \<0.0001                                                                                                                  
     Female                           639 (58.9%)                                   50 (69.4%)                               522 (38.1%)                                538 (42.3%)                           1749 (46.0%)
     Male                             446 (41.1%)                                   22 (30.6%)                               847 (61.9%)                                735 (57.7%)                           2050 (54.0%)
  **Race**                                                                          0.0032                                                                                                                    
     White                            1004 (92.5%)                                  68 (94.4%)                               1282 (93.6%)                               1217 (95.6%)                          3571 (94.0%)
     Black                            5 (0.5%)                                      1 (1.4%)                                 7 (0.5%)                                   13 (1.0%)                             26 (0.7%)
     Asian/Pacific islander           20 (1.8%)                                     2 (2.8%)                                 15 (1.1%)                                  7 (0.5%)                              44 (1.2%)
     Other                            13 (1.2%)                                     0 (0.0%)                                 14 (1.0%)                                  15 (1.2%)                             42 (1.1%)
     Unknown                          43 (4.0%)                                     1 (1.4%)                                 51 (3.7%)                                  21 (1.6%)                             116 (3.1%)
  **Hospital site**                                                                 0.4132                                                                                                                    
     Mayo Clinic Arizona              10 (0.9%)                                     0 (0.0%)                                 11 (0.8%)                                  8 (0.6%)                              29 (0.8%)
     Mayo Clinic Florida              0 (0.0%)                                      0 (0.0%)                                 3 (0.2%)                                   2 (0.2%)                              5 (0.1%)
     Mayo Clinic Rochester            1,072 (98.8%)                                 71 (98.6%)                               1,351 (98.7%)                              1,262 (99.1%)                         3,756 (98.9%)
     Patient seen at multiple sites   3 (0.3%)                                      1 (1.4%)                                 4 (0.3%)                                   1 (0.1%)                              9 (0.2%)

18.6% patients had tumor stage 4 at time of diagnosis. Cancer/tumor-related information are shown in Table [2](#T2){ref-type="table"}.

###### 

Tumor information.

                                                                **Normal weight individuals (*N* = 1,085)**   **Underweight individuals (*N* = 72)**   **Overweight individuals (*N* = 1369)**   **Obese individuals (*N* = 1,273)**   **Total (*N* = 3,799)**
  ------------------------------------------------------------- --------------------------------------------- ---------------------------------------- ----------------------------------------- ------------------------------------- -------------------------
  **Cancer side (transverse excluded)**                                                                       0.9922                                                                                                                   
     Missing                                                    148                                           14                                       169                                       157                                   488
     1 = Right                                                  426 (45.5%)                                   27 (46.6%)                               544 (45.3%)                               512 (45.9%)                           1509 (45.6%)
     2 = Left                                                   511 (54.5%)                                   31 (53.4%)                               656 (54.7%)                               604 (54.1%)                           1802 (54.4%)
  **Cancer side (transverse and rectum excluded)**                                                            0.4301                                                                                                                   
     Missing                                                    367                                           33                                       480                                       399                                   1279
     1 = Right                                                  426 (59.3%)                                   27 (69.2%)                               544 (61.2%)                               512 (58.6%)                           1509 (59.9%)
     2 = Left                                                   292 (40.7%)                                   12 (30.8%)                               345 (38.8%)                               362 (41.4%)                           1011 (40.1%)
  **Cancer location (transverse and recto-sigmoid excluded)**                                                 0.0366                                                                                                                   
     Missing                                                    184                                           16                                       232                                       205                                   637
     1 = Right                                                  426 (47.3%)                                   27 (48.2%)                               544 (47.8%)                               512 (47.9%)                           1509 (47.7%)
     2 = Left                                                   256 (28.4%)                                   10 (17.9%)                               282 (24.8%)                               314 (29.4%)                           862 (27.3%)
     3 = Rectum                                                 219 (24.3%)                                   19 (33.9%)                               311 (27.4%)                               242 (22.7%)                           791 (25.0%)
  **Tumor size**                                                                                              0.1007                                                                                                                   
     *N*                                                        905                                           56                                       1,123                                     1,068                                 3,152
     Mean (*SD*)                                                62.6 (131.2)                                  67.7 (128.5)                             61.2 (124.0)                              56.3 (111.4)                          60.0 (122.1)
     Median                                                     40.0                                          43.5                                     42.0                                      40.0                                  40.0
     Q1, Q3                                                     26.0, 60.0                                    30.0, 71.5                               27.0, 60.0                                25.0, 58.5                            25.0, 60.0
     Range                                                      (0.0--990.0)                                  (0.0--988.0)                             (0.0--990.0)                              (1.0--993.0)                          (0.0--993.0)
  **Regional lypmp node positive**                                                                            0.7389                                                                                                                   
     *N*                                                        791                                           45                                       1,027                                     979                                   2,842
     Mean (*SD*)                                                1.5 (3.1)                                     1.0 (1.9)                                1.6 (3.7)                                 1.5 (3.5)                             1.5 (3.5)
     Median                                                     0.0                                           0.0                                      0.0                                       0.0                                   0.0
     Q1, Q3                                                     0.0, 2.0                                      0.0, 1.0                                 0.0, 2.0                                  0.0, 1.0                              0.0, 1.0
     Range                                                      (0.0--24.0)                                   (0.0--8.0)                               (0.0--48.0)                               (0.0--25.0)                           (0.0--48.0)
  **Regional lymph node exam**                                                                                0.4553                                                                                                                   
     *N*                                                        1,012                                         66                                       1,306                                     1,225                                 3,609
     Mean (*SD*)                                                16.3 (16.1)                                   18.4 (19.7)                              16.0 (14.8)                               16.4 (14.1)                           16.2 (15.1)
     Median                                                     13.0                                          15.5                                     13.0                                      14.0                                  14.0
     Q1, Q3                                                     1.5, 24.0                                     0.0, 25.0                                4.0, 24.0                                 6.0, 24.0                             4.0, 24.0
     Range                                                      (0.0--89.0)                                   (0.0--84.0)                              (0.0--86.0)                               (0.0--81.0)                           (0.0--89.0)
  **Behavior**                                                                                                0.6505                                                                                                                   
     2                                                          12 (1.1%)                                     1 (1.4%)                                 21 (1.5%)                                 13 (1.0%)                             47 (1.2%)
     3                                                          1073 (98.9%)                                  71 (98.6%)                               1348 (98.5%)                              1260 (99.0%)                          3752 (98.8%)
  **Mixed stage**                                                                                             \<0.0001                                                                                                                 
     Missing                                                    43                                            4                                        48                                        63                                    158
     0                                                          16 (1.5%)                                     1 (1.5%)                                 40 (3.0%)                                 29 (2.4%)                             86 (2.4%)
     1                                                          287 (27.5%)                                   14 (20.6%)                               395 (29.9%)                               407 (33.6%)                           1103 (30.3%)
     2                                                          259 (24.9%)                                   20 (29.4%)                               342 (25.9%)                               301 (24.9%)                           922 (25.3%)
     3                                                          226 (21.7%)                                   14 (20.6%)                               311 (23.5%)                               302 (25.0%)                           853 (23.4%)
     4                                                          254 (24.4%)                                   19 (27.9%)                               233 (17.6%)                               171 (14.1%)                           677 (18.6%)
  **Follow-up years since cancer diagnosis**                                                                  \<0.0001                                                                                                                 
     *N*                                                        1,084                                         72                                       1,369                                     1,273                                 3,798
     Mean (*SD*)                                                5.4 (5.6)                                     3.4 (4.1)                                6.0 (5.8)                                 6.0 (5.4)                             5.8 (5.6)
     Median                                                     3.4                                           1.8                                      4.1                                       4.6                                   3.9
     Q1, Q3                                                     0.9, 8.4                                      0.6, 4.1                                 1.2, 9.7                                  1.5, 9.4                              1.2, 9.1
     Range                                                      (0.0--39.7)                                   (0.0--16.1)                              (0.0--32.8)                               (0.0--42.3)                           (0.0--42.3)

Survival Rates Based on BMI Categories Before Stage Stratification
------------------------------------------------------------------

With all stages combined together, the overall 5-years survival rates for underweight, normal weight, overweight and obese patients were 33, 56, 60, and 65%, respectively (*p* \< 0.001). The median survival for underweight, normal weight, overweight and obese was 38, 80, 106, and 114 months, respectively. To examine if these effects were stage-dependent, Kaplan-Meier estimates of overall survival since cancer diagnosis by BMI category and stage were done and are demonstrated in Table [3](#T3){ref-type="table"}. We also tried to visually show the association of BMI and overall mortality with Figure [1](#F1){ref-type="fig"} showing the non-linear pattern; corroborating prior findings and hypotheses. Consistently, the results show a significant disadvantage for the underweight individuals. There was a trend toward better survival in patients in the overweight and obese categories as compared to normal weight individuals.

###### 

Kaplan-Meier estimates of overall survival since cancer diagnosis.

  **Variable**           **Category**   **Total number of patients**   **Total number of events**   **5-years survival (95%CI)**   **10-years survival (95%CI)**   **15-years survival (95%CI)**   **Median survival (moths)**   ***P*-Value**
  ---------------------- -------------- ------------------------------ ---------------------------- ------------------------------ ------------------------------- ------------------------------- ----------------------------- ---------------
  BMI                    Normal         1,084                          590                          56.1% (53, 59.4)               40.3% (36.9, 43.9)              29.2% (25.7, 33.2)              80.4                          \<0.0001
  BMI                    Underweight    72                             48                           33% (22.9, 47.8)               21% (12.1, 36.3)                21% (12.1, 36.3)                37.7                          
  BMI                    Overweight     1,369                          713                          60.1% (57.4, 63.0)             46.2% (43.2, 49.3)              33.6% (30.4, 37.2)              105.7                         
  BMI                    Obese          1,273                          631                          65% (62.2, 67.9)               46.8% (43.6, 50.2)              31.9% (28.3, 35.9)              113.9                         
  BMI in stage 1 pts     Normal         287                            114                          75.7% (70.4, 81.5)             55.3% (48.6, 62.9)              41.6% (34.3, 50.4)              144.6                         0.553
  BMI in stage 1 pts     Underweight    14                             5                            80.8% (59.5, 100.0)            55.4% (30.0, 100.0)             55.4% (30.0, 100.0)             185                           
  BMI in stage 1 pts     Overweight     395                            154                          76.4% (71.9, 81.1)             61.1% (55.6, 67.2)              46.1% (39.8, 53.4)              161.1                         
  BMI in stage 1 pts     Obese          407                            167                          79.7% (75.5, 84.1)             57.2% (51.5, 63.5)              38.6% (32.1, 46.4)              146.6                         
  BMI in stage 2 pts     Normal         258                            132                          69% (63.1, 75.4)               42.7% (35.8, 50.8)              28.6% (21.5, 38.1)              105                           0.0093
  BMI in stage 2 pts     Underweight    20                             12                           42.1% (24.1, 73.6)             25.3% (10.2, 62.6)              25.3% (10.2, 62.6)              42.9                          
  BMI in stage 2 pts     Overweight     342                            153                          71.8% (66.7, 77.2)             53.8% (47.8, 60.6)              36.6% (30.0, 44.6)              134.3                         
  BMI in stage 2 pts     Obese          301                            126                          75.8% (70.7, 81.2)             56.5% (50.0, 63.8)              35.5% (28.0, 44.9)              150                           
  BMI in stage 3 pts     Normal         226                            106                          63.9% (57.4, 71.1)             49.2% (42.2, 57.4)              32.5% (24.5, 43.0)              118.3                         0.1405
  BMI in stage 3 pts     Underweight    14                             9                            31.3% (12.8, 76.7)             20.9% (6.3, 69.4)               %(,)                            39.1                          
  BMI in stage 3 pts     Overweight     311                            166                          59.8% (54.2, 65.9)             45.4% (39.6, 52.1)              32.6% (26.4, 40.3)              105.7                         
  BMI in stage 3 pts     Obese          302                            155                          63.7% (58.0, 69.9)             41.7% (35.4, 49.2)              30.2% (23.7, 38.5)              97.2                          
  BMI in stage 4 pts     Normal         254                            210                          14.1% (10.1, 19.6)             10% (6.6, 15.3)                 10% (6.6, 15.3)                 14.9                          0.0179
  BMI in stage 4 pts     Underweight    19                             19                           \% (,)                         \% (,)                          \% (,)                          4.5                           
  BMI in stage 4 pts     Overweight     233                            195                          14.3% (10.1, 20.1)             8.5% (5.2, 13.9)                6.8% (3.5, 13.1)                14.4                          
  BMI in stage 4 pts     Obese          171                            145                          12.1% (7.8, 18.8)              6.2% (2.6, 14.7)                6.2% (2.6, 14.7)                14.2                          
  BMI in stage 3/4 pts   Normal         480                            316                          37.1% (32.7, 42.1)             28.1% (23.9, 33.1)              20.1% (15.7, 25.8)              30.1                          \<0.0001
  BMI in stage 3/4 pts   Underweight    33                             28                           11.7% (4.2, 32.8)              7.8% (2.1, 28.8)                \% (,)                          16.6                          
  BMI in stage 3/4 pts   Overweight     544                            361                          40.4% (36.3, 45.1)             29.8% (25.7, 34.4)              21.53% (17.4, 26.6)             36.5                          
  BMI in stage 3/4 pts   Obese          473                            300                          44.7% (40.1, 49.8)             29.0% (24.5, 34.5)              21.4% (16.8, 27.2)              47.6                          

![Hazard ratio plot of pre diagnosis BMI. Our results here showing the "U"-shaped association corroborate some of the previously reported results from other studies. The association reflects that it is not that obesity is "protective" *per se*, but having a low BMI or being malnourished is a red flag and such a worse prognostic indicator, that it makes being overweight or obese have relatively better outcomes. However, outcomes do appear to get worse with rising BMI.](fonc-08-00620-g0001){#F1}

Stage-specific Survival Rates Based on BMI Categories
-----------------------------------------------------

Multivariable model as shown in Tables [4A--C](#T4){ref-type="table"} was done in each cancer stage, after controlling for pre-specified baseline and tumor characters as noted earlier. The results show that, the difference in overall survival was not statistically significant when underweight, overweight, and obese patients were compared to normal weight patients in stage 1 and stage 2, although there was a trend that underweight patients had a survival disadvantage. In stage 3 and 4 patients combined, underweight group demonstrated a significant disadvantage (HR = 1.96, *p* = 0.007) for overall survival compared to the normal weight group. In all the analyses, HR reported is in reference to the normal weight group. The unadjusted KM survival curves for BMI groups in stage 3 and 4 patients are displayed in Figure [2](#F2){ref-type="fig"}.

###### 

Multivariable model predicting overall mortality: stage 1 patients.

  **Variable**                                             **Category**             **HR (95%CI)**   ***P*-value**
  -------------------------------------------------------- ------------------------ ---------------- ---------------
  Age at diagnosis                                         Per 1 year increase      1.1 (1.1, 1.1)   \<0.001
  Gender                                                   Male vs. female          1.3 (1.1, 1.6)   0.0201
  Year of diagnosis                                        ≥2000 vs. \< 2000        1.4 (1.1 1.8)    0.0085
  Cancer location (transverse and rectosigmoid excluded)   Left vs. right           1.3 (1.0, 1.6)   0.0704
  Cancer location (transverse and rectosigmoid excluded)   Rectum vs. right         1.1 (0.9, 1.4)   0.437
  Pre-diagnosis BMI                                        Underweight vs. normal   2.4 (1.0, 6.0)   0.0539
  Pre-diagnosis BMI                                        Overweight vs. normal    0.9 (0.7, 1.2)   0.3375
  Pre-diagnosis BMI                                        Obese vs. normal         1.2 (1.0, 1.6)   0.1193

###### 

Multivariable model predicting overall mortality: stage 2 patients.

  **Variable**        **Category**                                     **HR (95% CI)**   ***P*-value**
  ------------------- ------------------------------------------------ ----------------- ---------------
  Age at diagnosis    Per 1 year increase                              1.1 (1.1, 1.1)    \<0.001
  Gender              Male vs. female                                  1.5 (1.2, 1.9)    \<0.001
  Year of diagnosis   ≥2000 vs. \< 2000                                1.0 (0.8, 1.3)    0.9472
  Cancer location     Left vs. right                                   1.4 (1.1, 1.8)    0.0034
  Cancer location     Rectum vs. right                                 1.8 (1.4, 2.5)    \<0.001
  Pre-diagnosis BMI   Underweight vs. normal up to 5 years follow-up   1.8 (0.9, 3.5)    0.1062
  Pre-diagnosis BMI   Underweight vs. normal after 5 years follow-up   0.4 (0.1, 3.2)    0.414
  Pre-diagnosis BMI   Overweight vs. normal                            0.8 (0.6, 1.0)    0.086
  Pre-diagnosis BMI   Obese vs. normal                                 0.9 (0.7, 1.2)    0.3877

###### 

Multivariable model predicting overall mortality: stage 3, 4 patients.

  **Variable**        **Category**             **HR (95% CI)**    ***P*-value**
  ------------------- ------------------------ ------------------ ---------------
  Age at diagnosis    Per 1 year increase      1.0 (1.0, 1.0)     \<0.001
  Gender              Male vs. female          1.1 (0.9, 1.3)     0.2515
  Year of diagnosis   ≥2000 vs. \< 2000        0.9 (0.8, 1.1)     0.3164
  Cancer location     Left vs. right           0.9 (0.8, 1.1)     0.4083
  Cancer location     Rectum vs. right         0.9 (0.7, 1.0)     0.1019
  Pre-diagnosis BMI   Underweight vs. normal   2.0 (1.2, 3.2)     0.0073
  Pre-diagnosis BMI   Overweight vs. normal    1.0 (0.81, 1.15)   0.719
  Pre-diagnosis BMI   Obese vs. normal         0.9 (0.8, 1.1)     0.5002

![Overall survival since diagnosis by BMI for stage 3 or 4 patients. Outcomes are significantly different based on the different BMI groups with significantly worse in the underweight group of patients with CRC.](fonc-08-00620-g0002){#F2}

Change in BMI as Time-dependent Covariate vs. Mortality
-------------------------------------------------------

When post-diagnosis BMI was analyzed as time-dependent covariates for stage 4 patients, being underweight (HR = 2.6 vs. normal, *p* \< 0.001) was a significant predictor for worse survival. Post-diagnosis BMI drop more than 10% from either a previous time (HR = 1.88, *p* = 0.002) or pre-diagnosis time (HR = 1.61, *p* \< 0.001) was associated with worse overall survival after adjusting for baseline variables. Similar trends were also noted for a post-diagnosis BMI drop by 5--10% from previous time (HR = 1.47, *p* = 0.023) or pre-diagnosis time (HR = 0.84, *p* = 0.302), respectively. Multivariable model predicting overall mortality is demonstrated in Tables [5A--C](#T5){ref-type="table"}.

###### 

Multivariable model predicting overall mortality: stage 4 patients, post-diagnosis BMI is used as time-dependent covariate.

  **Variable**         **Category**             **HR (95% CI)**   ***P*-value**
  -------------------- ------------------------ ----------------- ---------------
  Age at diagnosis     Per 1 year increase      1.0 (1.0, 1.0)    \<0.001
  Gender               Male vs. female          1.1 (0.9, 1.4)    0.2636
  Year of diagnosis    ≥2000 vs. \< 2000        0.9 (0.7, 1.2)    0.5434
  Cancer location      Left vs. right           0.8 (0.6, 1.0)    0.0543
  Cancer location      Rectum vs. right         0.9 (0.7, 1.1)    0.2532
  Post-diagnosis BMI   Underweight vs. normal   2.6 (1.6, 4.1)    \<0.001
  Post-diagnosis BMI   Overweight vs. normal    0.9 (0.7, 1.1)    0.3938
  Post-diagnosis BMI   Obese vs. normal         0.9 (0.7, 1.1)    0.2836

###### 

Multivariable model predicting overall mortality: post-diagnosis BMI change from previous time as time-dependent covariate.

  **Variable**                                      **Category**                                            **HR (95% CI)**   ***p*-value**
  ------------------------------------------------- ------------------------------------------------------- ----------------- ---------------
  Age at diagnosis                                  Age at diagnosis                                        1.0 (1.0, 1.0)    \<0.001
  Gender                                            Male vs. female                                         1.1 (0.9, 1.3)    0.4894
  Year of diagnosis                                 ≥2000 vs. \< 2000                                       0.9 (0.7, 1.2)    0.3913
  Cancer location                                   Left vs. right                                          0.8 (0.7, 1.0)    0.0915
  Cancer location                                   Rectum vs. right                                        0.9 (0.7, 1.2)    0.4713
  Change of post-diagnosis BMI from previous time   Dropped by 5--10% vs. no more than 5% change            1.5 (1.1, 2.1)    0.023
  Change of post-diagnosis BMI from previous time   Dropped by more than 10% vs. no more than 5% change     1.9 (1.3, 2.8)    0.0024
  Change of post-diagnosis BMI from previous time   Increased by 5--10% vs. no more than 5% change          0.9 (0.6, 1.4)    0.6341
  Change of post-diagnosis BMI from previous time   Increased by more than 10% vs. no more than 5% change   0.7 (0.4, 1.4)    0.3197

###### 

Multivariable model predicting overall mortality: post-dx BMI change from pre dx time as time-dependent covariate.

  **Variable**                                           **Category**                                            **HR (95% CI)**   ***P*-value**
  ------------------------------------------------------ ------------------------------------------------------- ----------------- ---------------
  Age at diagnosis                                       Age at diagnosis                                        1.0 (1.0, 1.0)    \<0.001
  Gender                                                 Male vs. female                                         1.1 (0.9, 1.3)    0.6417
  Year of diagnosis                                      ≥2000 vs. \< 2000                                       0.9 (0.7, 1.2)    0.5618
  Cancer location                                        Left vs. right                                          0.8 (0.7, 1.0)    0.1011
  Cancer location                                        Rectum vs. right                                        0.9 (0.7, 1.2)    0.6125
  Change of post-diagnosis BMI from pre diagnosis time   Dropped by 5--10% vs. no more than 5% change            0.8 (0.6, 1.2)    0.3025
  Change of post-diagnosis BMI from pre diagnosis time   Dropped by more than 10% vs. no more than 5% change     1.6 (1.2, 2.1)    \<0.001
  Change of post-diagnosis BMI from pre diagnosis time   Increased by 5--10% vs. no more than 5% change          0.5 (0.3, 1.0)    0.0338
  Change of post-diagnosis BMI from pre diagnosis time   Increased by more than 10% vs. no more than 5% change   0.5 (0.3, 1.0)    0.0405

Discussion {#s4}
==========

In this retrospective study of 3,799 patients diagnosed with CRC at our institution, the patients who were underweight within 6 months prior to diagnosis had increased mortality compared to normal weight, overweight and obese patients. We found statistically significant association between underweight BMI and survival for stage III and IV CRC, and a trend of underweight BMI category being at disadvantage for stage I and II CRC. The patients with CRC who were overweight had a trend of better survival in the analysis compared to patients belonging to other BMI categories. These findings emphasize the importance of BMI as an independent prognostic determinant for CRC.

The effect of BMI on survival of CRC patients has been extensively investigated and the results have been mixed. In a prior review, our group had summarized the postulated mechanisms linking obesity to the development colorectal cancer; these are summarized in Figure [3](#F3){ref-type="fig"} ([@B14]). Previously few studies have shown that there is no association between BMI and CRC-specific survival ([@B15]). In an observational study of 1,053 stage III colon cancer patients in the United States, the investigators followed BMI changes during and 6 months after chemotherapy and found no association between BMI and mortality ([@B16]). A study conducted in Germany also reported that there is no statistically significant relationship exists between BMI and survival in CRC patients ([@B17]). Importantly, the aforesaid study was limited by the fact that BMI information was taken by self-administered questionnaire and patients were enrolled 4 years post-diagnosis that might have lead losing data of patients who deceased due to advanced CRC ([@B17]). However, in the same study a meta-analysis was performed incorporating 5 studies and showed that underweight and overweight BMI categories are associated with worse and better survival in CRC patients, respectively ([@B17]). Various investigations have shown "J-shaped" relationship between BMI and outcomes of CRC, with poor survival at extremes of BMI and improved survival at normal or overweight BMI. In another study that did show the association between BMI and mortality in CRC patients, underweight (BMI \< 18.5, HR: 2.65) and class II or III obesity (BMI≥35, HR: 1.33) were noted to be associated with higher mortality; and low-overweight (BMI 25 to \<28, HR: 0.75) and high-overweight (BMI 28 to \<30, HR: 0.52) exhibited lower mortality ([@B18]). Our findings, literature review and hypotheses prior to conducting the analyses correspond with these findings. We consistently found underweight BMI category associated with poor survival. Consistent with our results, the BMI of underweight and overweight as indicators of poor and better survival in CRC patients, respectively are also reported by Australian ([@B19]) and Iranian ([@B20]) studies.

![Postulated mechanisms linking obesity and development of colon cancer (reproduced with permission---Kasi et al. ([@B14]).](fonc-08-00620-g0003){#F3}

We found likelihood of dying specific to different BMI categories for advanced CRC patients. Even though there was similar direction of effect for patients with early stage disease, the magnitude of association was not statistically significant. This is likely due to the sample size of patients with available BMI information. The effect might be related to cancer-related cachexia and underlying biology in late stage disease patients. Overweight BMI, which is shown to be a predictor of better survival in CRC patients, does not necessarily mean that being overweight or obesity is good. Potentially it may be because that underweight BMI have such a poor prognosis, that obesity seems to be beneficial. The subsets of individuals in the overweight or obese category probably have reserves to tolerate some cancer and/or treatment related side effects better as compared normal or underweight individuals.

We also estimated the effect of serial drop in BMI on survival for stage IV CRC patients. The findings highlight that post-diagnosis BMI drop more than 10% is associated with worse survival compared to BMI drop \< 10%. Kocarnik et al. studied 2,049 CRC patients from 4 cancer registries and reported post-diagnosis weight loss as an indicator of poor CRC-specific survival (HR: 1.25; 95% CI: 1.13--1.39) ([@B21]). Our study is different in regards that we calculated survival for serial BMI drop at 1st, 2nd, and 3rd months post-diagnosis, while Kocarnik et al. estimated survival of CRC patients at 5-years post-diagnosis and participants were registered within 2 years after diagnosis ([@B21]).

Research has indicated that several lifestyle modifications including exercise and weight loss are protective against development of CRC ([@B22], [@B23]). One the other hand, obesity is reported as one of the risk factors of CRC occurrence ([@B4], [@B24]). The various possible mechanisms leading to development of colon cancer in obese patients are shown in Figure [3](#F3){ref-type="fig"}. Likewise, few studies have examined the association between lifestyle factors and CRC mortality ([@B25]). Physical activity is still recommended after CRC diagnosis in the metastatic setting ([@B26], [@B27]) but losing "healthy" weight is not encouraged because of deleterious effects of malnutrition. Weight loss has the most deleterious prognostic effects in CRC patients especially with advanced disease.

Strengths of our study include large sample size (*n* = 3,799), availability of stage-specific data and estimation of CRC survival with serial drop in BMI. This study is limited by its retrospective design and lack of information about the comorbid and confounding factors which might have played role in survival. Furthermore, there is potential of reporting bias since only 14% (*n* = 3,799) patients, out of total (*n* = 26,908) seen at our institution, were included in the analysis whose BMI information was available. We adjusted for this as whenever BMI values were not available and instead height and weight information was available, we calculated BMI manually. Additional limitations include the smaller subset of individuals with serial BMI data that we used for the weight loss or drop in BMI analyses. Furthermore, therapy that these patients got was likely heterogeneous. With BMI being a dynamic variable, the same question posed by our study group can potentially be studied and analyzed through other approaches as well. However, more of value would be to studying these variables in prospective studies, especially intervention studies e.g., improving BMI or reducing rate of weight loss in malnourished patients e.g., with nutrition counseling.

Conclusion {#s5}
==========

BMI is an important factor determining outcomes of CRC patients and the complex relationship is further corroborated by our findings. More importantly, our research could have implications on management guidelines of patients with CRC, particularly consideration of regular monitoring of BMI and potentially alerting patients, providers as well as caregivers to take steps to help stop the decline. Studies designed to study this prospectively would be of value. Studying serial BMI could serve as a dynamic biomarker that could be potentially modifiable.
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